Irwin Goldstein1, Richard Chambers2, WingYu Tang3, Vera Stecher4, Tarek Hassan4. 1. Sexual Medicine, Alvarado Hospital, San Diego, CA, USA. 2. Biostatistics, Pfizer Inc, Collegeville, PA, USA. 3. Patient & Health Impact, Pfizer Inc, New York, NY, USA. 4. Medical Affairs, Pfizer Inc, New York, NY, USA.
Abstract
AIMS: To evaluate the relationship of comorbidities (cardiovascular disease [CVD], diabetes mellitus [DM] and depression) with erectile dysfunction (ED) and age using real-world claims data from 48 million men in the United States. METHODS: This was a cross-sectional, non-interventional study in men aged ≥18 years using data from the Truven Health MarketScan® and Medicare Supplemental Research Databases from January 2010 to December 2015, with an observational period of January 2011 to December 2014 to allow for 12 months pre- and post-index. Comorbidity rate was compared between ED and non-ED groups by age using the χ2 (bivariate) test. Comorbidity relationship to ED after controlling for categorical variables was assessed using logistic regression analysis. RESULTS: In all, 48 004 379 men were in the database. Of the 9 839 578 who met the inclusion criteria, 573 313 (6%) were ED patients and 9 266 265 (94%) were non-ED patients. ED diagnosis increased decade to decade from 18-29 years to 50-59 years but decreased from 60-69 years to ≥90 years. ED patients had a higher prevalence of CVD, DM and depression than non-ED patients in all periods (P < .0001). After controlling for potential demographic and baseline confounders, the association between ED and CVD, DM and depression remained significant for each age group beginning at 30-39 years (P < .0001). DISCUSSION: Conversations with patients concerning ED should be comprehensive regardless of patient age, in particular in those who have CVD, DM and/or depression. CONCLUSIONS: In the real-world setting, ED diagnosis was associated with CVD, DM and depression across age groups, suggesting a need for inquiry about the potential for comorbidities among these men as a preventative measure against potentially serious future events.
AIMS: To evaluate the relationship of comorbidities (cardiovascular disease [CVD], diabetes mellitus [DM] and depression) with erectile dysfunction (ED) and age using real-world claims data from 48 million men in the United States. METHODS: This was a cross-sectional, non-interventional study in men aged ≥18 years using data from the Truven Health MarketScan® and Medicare Supplemental Research Databases from January 2010 to December 2015, with an observational period of January 2011 to December 2014 to allow for 12 months pre- and post-index. Comorbidity rate was compared between ED and non-ED groups by age using the χ2 (bivariate) test. Comorbidity relationship to ED after controlling for categorical variables was assessed using logistic regression analysis. RESULTS: In all, 48 004 379 men were in the database. Of the 9 839 578 who met the inclusion criteria, 573 313 (6%) were ED patients and 9 266 265 (94%) were non-ED patients. ED diagnosis increased decade to decade from 18-29 years to 50-59 years but decreased from 60-69 years to ≥90 years. ED patients had a higher prevalence of CVD, DM and depression than non-ED patients in all periods (P < .0001). After controlling for potential demographic and baseline confounders, the association between ED and CVD, DM and depression remained significant for each age group beginning at 30-39 years (P < .0001). DISCUSSION: Conversations with patients concerning ED should be comprehensive regardless of patient age, in particular in those who have CVD, DM and/or depression. CONCLUSIONS: In the real-world setting, ED diagnosis was associated with CVD, DM and depression across age groups, suggesting a need for inquiry about the potential for comorbidities among these men as a preventative measure against potentially serious future events.
Authors: Camilla R Madeira; Fernanda S Tonin; Mariana M Fachi; Helena H Borba; Vinicius L Ferreira; Leticia P Leonart; Aline F Bonetti; Rogerio P Moritz; Angela C L B Trindade; Alan G Gonçalves; Fernando Fernandez-Llimos; Roberto Pontarolo Journal: World J Urol Date: 2020-05-09 Impact factor: 4.226
Authors: Giuseppe Defeudis; Rossella Mazzilli; Marta Tenuta; Giovanni Rossini; Virginia Zamponi; Soraya Olana; Antongiulio Faggiano; Paolo Pozzilli; Andrea M Isidori; Daniele Gianfrilli Journal: Diabetes Metab Res Rev Date: 2021-09-21 Impact factor: 8.128
Authors: Jim Z Li; Terence A Maguire; Kelly H Zou; Lauren J Lee; Shaantanu S Donde; David G Taylor Journal: Int J Clin Pract Date: 2022-03-20 Impact factor: 3.149
Authors: George T Kedia; Stefan Ückert; Dimitrios Tsikas; Armin J Becker; Markus A Kuczyk; Andreas Bannowsky Journal: J Clin Med Date: 2020-09-16 Impact factor: 4.241
Authors: Jong Keun Kim; Myoung Jin Jang; Bo Hyun Kim; Ki Ryung Choi; Geehyun Song; Ha Chul Shin; Nayoung Suh; Yong Man Kim; Dalsan You; Tai Young Ahn; Choung-Soo Kim Journal: Investig Clin Urol Date: 2019-12-17